Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors
- 1 January 2015
- journal article
- focus on-quality
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 11 (1), 47-54
- https://doi.org/10.1200/jop.2014.001492
Abstract
Among patients receiving myelosuppressive chemotherapy for metastatic cancer in US clinical practice, febrile neutropenia is a frequent complication associated with morbidity, mortality, and economic costs.Keywords
This publication has 31 references indexed in Scilit:
- A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropeniaJournal of Medical Economics, 2013
- Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective studyExperimental and Therapeutic Medicine, 2011
- Risk of mortality in patients with cancer who experience febrile neutropeniaCancer, 2010
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005
- 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyBMJ, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- The economics of febrile neutropenia: implications for the use of colony-stimulating factorsEuropean Journal of Cancer, 1998
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.Journal of Clinical Oncology, 1990